Related Experiment Video

Updated: May 11, 2026

Single Nuclei Isolation from Coronary Endarterectomy Tissue of Coronary Artery Bypass Graft Patients
09:09

Single Nuclei Isolation from Coronary Endarterectomy Tissue of Coronary Artery Bypass Graft Patients

Published on: April 3, 2026

Proteomics of plaques and novel sources of potential biomarkers for atherosclerosis

Onno B Bleijerveld1, Ya-Nan Zhang, Serap Beldar

  • 1Laboratory of Experimental Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands.

Proteomics. Clinical Applications
|May 15, 2013
PubMed

Insights

Proteomics offers new hope for identifying biomarkers to detect cardiovascular disease (CVD) and atherosclerosis early. Research explores plaque proteomes, circulating cells, and extracellular vesicles for personalized risk assessment and treatment.

Area of Science:

  • Cardiovascular research
  • Biomarker discovery
  • Proteomics

Background:

  • Cardiovascular disease (CVD) is a leading global cause of mortality.
  • Atherosclerosis, the underlying pathology of CVD, involves complex interactions of lipid metabolism, inflammation, and immunity.
  • Current risk factors inadequately predict disease onset, necessitating novel biomarkers.

Purpose of the Study:

  • To review advancements in proteomic profiling for identifying cardiovascular disease biomarkers.
  • To explore novel biomarker sources like atherosclerotic plaques, circulating cells, and extracellular vesicles.
  • To highlight the role of protein post-translational modifications (PTMs) in atherosclerosis.

Main Methods:

  • Proteome profiling of atherosclerotic plaques.
  • Analysis of circulating cells and plasma extracellular vesicles.
  • Utilizing longitudinal biobanking data (e.g., Athero-Express study).

Main Results:

  • Progress in identifying potential protein biomarkers from plaque proteomes.
  • Identification of novel biomarker sources beyond traditional methods.
  • Demonstration of plaque proteins discovered through biobanking studies.

Conclusions:

  • Proteomics is crucial for discovering novel biomarkers for early CVD and atherosclerosis detection.
  • Circulating cells and extracellular vesicles represent promising sources for biomarker development.
  • Investigating protein PTMs in atherosclerosis holds potential for future biomarker strategies.

Keywords:
AtherosclerosisAtherosclerotic plaqueBiomarkersCirculating cellsPlasma extracellular vesicles

More Related Videos

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis08:01

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

Quantification of Atherosclerosis in Mice06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...